VU-0090157

VU-0090157

VU-0090157 is a chemical compound that has been studied for its potential effects on the central nervous system. It is primarily known as a selective positive allosteric modulator of the metabotropic glutamate receptor 4 (mGluR4). This compound has been of interest in the field of neuroscience for its potential therapeutic applications in neurological disorders.

Chemical Structure and Properties

VU-0090157 is characterized by its specific chemical structure that allows it to interact selectively with mGluR4. The compound's molecular formula is C₁₉H₁₈N₂O₃, and it has a molecular weight of 322.36 g/mol. The structure includes a pyridine ring, which is crucial for its activity as a modulator.

Mechanism of Action

VU-0090157 functions as a positive allosteric modulator (PAM) of the mGluR4 receptor. This means that it binds to a site on the receptor distinct from the orthosteric site (where the endogenous ligand glutamate binds) and enhances the receptor's response to glutamate. By modulating mGluR4 activity, VU-0090157 can influence neurotransmission and synaptic plasticity, which are critical processes in the brain.

Therapeutic Potential

Research into VU-0090157 has suggested potential therapeutic applications in several neurological and psychiatric disorders. These include:

• Parkinson's Disease: mGluR4 modulation has been shown to have neuroprotective effects and may help alleviate motor symptoms associated with Parkinson's disease.
• Anxiety and Depression: Modulation of glutamatergic signaling is a promising approach for treating mood disorders, and mGluR4 PAMs like VU-0090157 are being investigated for their anxiolytic and antidepressant effects.
• Schizophrenia: Altered glutamate signaling is implicated in schizophrenia, and mGluR4 modulators may offer a novel treatment strategy.

Research and Development

VU-0090157 is primarily used in preclinical research settings. Studies have demonstrated its efficacy in animal models, but further research is needed to evaluate its safety and effectiveness in humans. The compound is part of ongoing research efforts to develop new treatments for neurological disorders by targeting glutamatergic pathways.

Safety and Pharmacokinetics

As of the latest research, detailed pharmacokinetic and safety profiles of VU-0090157 in humans are not fully established. Preclinical studies focus on understanding its bioavailability, metabolism, and potential side effects in animal models.

Also see

• Metabotropic glutamate receptor 4
• Positive allosteric modulator
• Glutamatergic system
• Parkinson's disease
• Neurotransmission